The potential for rapid antigen testing for mucormycosis in the context of COVID-19

References

• Thornton CR. Detection of the ‘big five’ mold killers of humans: Aspergillus, Fusarium, Lomentospora, Scedosporium and Mucormycetes. Adv Appl Microbiol. 2020;110:1–61.
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Bosco SMG, de Hoog S, et al. Fungal infections in animals: a patchwork of different situations. Med Mycol. 2018;56(suppl_1):S165–S187. doi: 10.1093/mmy/myx104
   PubMedGoogle Scholar
• Ghosh AK, Singh R, Reddy S, et al. Evaluation of environmental Mucorales contamination in and around the residence of COVID-19-associated mucormycosis patients. Front Cell Infect Microbiol. 2022;12:953750. DOI:10.3389/fcimb.2022.953750
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Tirado-Sánchez A, Calderón L, et al. Mucormycosis in children: a study of 22 cases in a Mexican hospital. Mycoses. 2014;57:79–84. DOI:10.1111/myc.12233
   PubMed Web of Science ®Google Scholar
• Danion F, Coste A, Le Hyaric C, et al. What is new in pulmonary mucormycosis? J Fungi. 2023;9(3):307. doi: 10.3390/jof9030307
   Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34. doi: 10.1016/j.cmi.2018.07.011
   PubMed Web of Science ®Google Scholar
• Monte Junior ES D, dos Santos, M.E.L, Ribeiro IB, et al. Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020;53(6):746–749. doi: 10.5946/ce.2020.180
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(S1):S23–S34. doi: 10.1093/cid/cir866
   PubMedGoogle Scholar
• Taj-Aldeen SJ, Gamaletsou MN, Rammaert B, et al. Bone and joint infections caused by mucormycetes: a challenging osteoarticular mycosis of the twenty-first century. Med Mycol. 2017;55:691–704. DOI:10.1093/mmy/myw136
   PubMed Web of Science ®Google Scholar
• Walther G, Wagner L, Kurzai O. Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa. J Fungi. 2019;5(4):106. doi: 10.3390/jof5040106
   Web of Science ®Google Scholar
• Davies GE, Thornton CR. Development of a monoclonal antibody and a lateral-flow device specific to Rhizopus arrhizus (syn. R. oryzae), the principal global agent of mucormycosis in humans. J Fungi. 2022;8(7):756. doi: 10.3390/jof8070756.
   Web of Science ®Google Scholar
• Osaigbovo II, Ekeng BE, Davies AA, et al. Mucormycosis in Africa: epidemiology, diagnosis and treatment outcomes. Mycoses. 2023;66(7):555–562. doi: 10.1111/myc.13581
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes and Metab Syndr: Clin Res Rev. 2021;15(4):102146. doi: 10.1016/j.dsx.2021.05.019
   PubMed Web of Science ®Google Scholar
• Laternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo study (2005-2007). Clin Infect Dis. 2012;54(suppl 1):S35–S43. doi: 10.1093/cid/cir880
   PubMedGoogle Scholar
• Patel A, Kaur H, Xess I, et al. A multicentre observation study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):.e944.9–.e944.15. doi: 10.1016/j.cmi.2019.11.021
   Web of Science ®Google Scholar
• Skiada A, Drogari-Apiranthitou M, Pavleas I, et al. Global cutaneous mucormycosis: a systematic review. J Fungi. 2022;8(2):194. doi: 10.3390/jof8020194
   Web of Science ®Google Scholar
• Buil JB, van Zanten ARH, Bentvelsen RG, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill. 2021;26(23):ii=2100510. doi: 10.2807/1560-7917.ES.2021.26.23.2100510
   PubMedGoogle Scholar
• Zaki SM, Elkholy IM, Elkady NA, et al. Mucormycosis in Cairo, Egypt: review of 10 reported cases. Med Mycol. 2014;52:1–8. DOI:10.3109/13693786.2013.809629
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(S1):S16–22. doi: 10.1093/cid/cir865
   PubMedGoogle Scholar
• Nicolás FE, Murcia L, Navarro E, et al. Mucorales species and macrophages. J Fungi. 2020;6(2):94. doi: 10.3390/jof6020094
   Web of Science ®Google Scholar
• Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi. 2021;7(2):88. doi: 10.3390/jof7020088
   Web of Science ®Google Scholar
• Xhu Y, Liu Y, Hu M, et al. Breakthrough mucormycosis in two cases of hematological malignancies successfully treated with amphotericin B colloidal dispersion. Med Clin Res. 2022;7(12):01–06.
   Google Scholar
• Walsh TJ, Hospenthal DR, Petraitis V, et al. Necrotizing mucormycosis of wounds following combat injuries, natural disasters, burns, and other trauma. J Fungi. 2019;5(3):57. doi: 10.3390/jof5030057
   Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26. doi: 10.3390/jof5010026
   Web of Science ®Google Scholar
• Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases – Estimate precision. J Fungi. 2017;3(4):57. doi: 10.3390/jof3040057
   Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523. doi: 10.3390/microorganisms9030523
   PubMed Web of Science ®Google Scholar
• Sarfraz Z, Sarfraz A, Jaiswal V, et al. The past, present and future of COVID-19 associated mucormycosis: a rapid review. J Prim Care Community Health. 2022;13:1–8. DOI:10.1177/21501319221099476
   Web of Science ®Google Scholar
• Singh D, Kaur H, Kajal NC. COVID-19 and rhino-orbital mucormycosis – a case report. Int J Pul & Res Sci. 2021;5(1):555654. doi: 10.19080/IJOPRS.2021.05.555654
   Google Scholar
• Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932–2938. doi: 10.4103/ijo.IJO_1627_21
   PubMed Web of Science ®Google Scholar
• Ghazi BK, Rackimuthu S, Wara UU. Rampant increase in cases of mucormycosis in India and Pakistan: a serious cause for concern during the ongoing COVID-19 pandemic. Am J Trop Med Hyg. 2102;105(5):1144–1147. doi: 10.4269/ajtmh.21-0608
   PubMed Web of Science ®Google Scholar
• Almyroudi MP, Akinosoglou K, Rello J, et al. Clinical phenotypes of COVID-19 associated mucormycosis (CAM): a comprehensive review. Diagnostics. 2022;12(12):3092. doi: 10.3390/diagnostics12123092
   Web of Science ®Google Scholar
• Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3(7):e543–552. doi: 10.1016/S2666-5247(21)00237-8
   PubMedGoogle Scholar
• Muthu V, Rudramurthy SM, Chakrabarti A, et al. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathol. 2021;186(6):739–754. doi: 10.1007/s11046-021-00584-8.
   PubMed Web of Science ®Google Scholar
• Borkar SG. Mucormycosis: a surge in Mucorales fungal infection in post-Covid patients in Indian States and insight into known and unknown factors. Int J Global Health. 2021;1(3):26–60. doi: 10.14302/issn.2693-1176.ijgh-21-3907
   Google Scholar
• Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir Med. 2021;9(8):e77. doi: 10.1016/S2213-2600(21)00265-4
   PubMed Web of Science ®Google Scholar
• Bilgic A, Kodjikian L, Sudhalkar A, et al. Risk factors for COVID-19 associated mucormycosis: the ophthalmologist’s perspective. J Fungi. 2022;8(3):271. doi: 10.3390/jof8030271
   Web of Science ®Google Scholar
• Radotra B, Challa S. Pathogenesis and pathology of COVID-19-associated mucormycosis: what is new and why? Curr Fungal Infect Rep. 2022;16(4):206–220. doi: 10.1007/s12281-022-00443-z
   PubMed Web of Science ®Google Scholar
• Janjua OS, Shaikh MS, Fareed MA, et al. Dental and oral manifestations of COVID-19 related mucormycosis: diagnoses, management strategies and outcomes. J Fungi. 2022;8(1):44. doi: 10.3390/jof8010044
   Web of Science ®Google Scholar
• Benhadid-Brahmi Y, Hamane S, Soyer B, et al. COVID-19-associated mold infection: a case report of aspergillosis and mucormycosis and a literature review. J Med Mycol. 2022;32(1):101231. doi: 10.1016/j.mycmed.2021.101231
   PubMed Web of Science ®Google Scholar
• Casalini G, Giacomelli A, Ridolfo A, et al. Invasive fungal infections complicating COVID-19: a narrative review. J Fungi. 2021;7(11):921. doi: 10.3390/jof7110921
   Web of Science ®Google Scholar
• Ezeokoli O, Gcilitshana O, Pohl CH. Risk factors for fungal co-infections in critically Ill COVID-19 patients, with a focus on immunosuppressants. J Fungi. 2021;7(7):545. doi: 10.3390/jof7070545
   Web of Science ®Google Scholar
• Tabarsi P, Khalili N, Pourabdollah M, et al. Case report: COVID-19-associated rhinosinusitis mucormycosis caused by Rhizopus arrhizus; a rare but potentially fatal infection occurring after treatment with corticosteroids. Am J Trop Med Hyg. 2021;105(2):449–453. doi: 10.4269/ajtmh.21-0359
   PubMed Web of Science ®Google Scholar
• John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for Mucormycosis. J Fungi. 2021;7(4):298. doi: 10.3390/jof7040298
   Web of Science ®Google Scholar
• Özbek L, Topçu U, Manay M, et al. COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases. Clin Microbiol Infect. 2023;29(6):722–731. doi: 10.1016/j.cmi.2023.03.008
   PubMed Web of Science ®Google Scholar
• Mélida H, Sain D, Stajich JE, et al. Deciphering the uniqueness of mucoromycotina cell walls by combining biochemical and phylogenetic approaches. Environ Microbiol. 2015;17(5):1649–1662. doi: 10.1111/1462-2920.12601
   PubMed Web of Science ®Google Scholar
• Davies G, Rolle A-M, Maurer A, et al. Towards translational immunoPET/MR imaging of invasive pulmonary aspergillosis: the humanised monoclonal antibody JF5 detects Aspergillus lung infections in vivo. Theranostics. 2017;7(14):3398–3414. doi: 10.7150/thno.20919
   PubMed Web of Science ®Google Scholar
• Dichtl K, Seybold U, Ormanns S, et al. Evaluation of a novel Aspergillus antigen enzyme-linked immunosorbent assay. J Clin Microbiol. 2019;57(7):e00136–19. doi: 10.1128/JCM.00136-19
   PubMed Web of Science ®Google Scholar
• Egger M, Penziner S, Dichtl K, et al. Performance of the Euroimmun Aspergillus antigen ELISA for the diagnosis of invasive pulmonary aspergillosis in bronchoalveolar lavage fluid. J Clin Microbiol. 2022;60(4):e0021522. doi: 10.1128/jcm.00215-22
   PubMed Web of Science ®Google Scholar
• Thornton CR. Development of an immunochromatographic lateral-flow device for the rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 2008;15(7):1095–1105. doi: 10.1128/CVI.00068-08
   PubMed Web of Science ®Google Scholar
• Schwenck J, Maurer A, Beziere N, et al. Antibody-guided molecular imaging of Aspergillus lung infections in leukemia pateints. J Nucl Med. 2022;63(9):1450–1451. doi: 10.2967/jnumed.121.263251
   Web of Science ®Google Scholar
• Malhotra HS, Gupta P, Mehrotra D, et al. COVID-19 associated mucormycosis: staging and management recommendations (report of a multi-disciplinary expert committee). J Oral Biol Craniofac Res. 2021;11(4):569–580. doi: 10.1016/j.jobcr.2021.08.001
   PubMedGoogle Scholar
• Lackner N, Posch W, Lass-Flörl C. Microbiological and molecular diagnosis of mucormycosis: from old to new. Microorganisms. 2021;9(7):1518. doi: 10.3390/microorganisms9071518
   PubMed Web of Science ®Google Scholar
• Murray J, Lu ZA, Miller K, et al. Dual disseminated aspergillosis and mucormycosis diagnosed at autopsy: a report of two cases of coinfection and a review of the literature. J Fungi. 2023;9(3):357. doi: 10.3390/jof9030357
   Web of Science ®Google Scholar
• Sadamoto S, Mitsui Y, Nihonyanagi Y, et al. Comparison approach for identifying missed invasive fungal infections in formalin-fixed, paraffin-embedded autopsy specimens. J Fungi. 2022;8(4):337. doi: 10.3390/jof8040337
   Web of Science ®Google Scholar
• Shao J, Wan Z, Li R, et al. Species identification and delineation of pathogenic Mucorales by matrix-assisted laser desorption ionisation-time of flight mass spectrometry. J Clin Microbiol. 2018;56(4):e01886–17. doi: 10.1128/JCM.01886-17
   PubMed Web of Science ®Google Scholar
• Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020;6(4):265. doi: 10.3390/jof6040265
   Web of Science ®Google Scholar
• Johnson AK, Ghazarian Z, Cendrowski KD, et al. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep. 2021;32:64–67. DOI:10.1016/j.mmcr.2021.03.006
   PubMed Web of Science ®Google Scholar
• Arana C, Ramírez REC, Xipelli M, et al. Mucormycosis associated with COVID-19 in two kidney transplant patients. Transpl Infect Dis. 2021;23(4):e13652. doi: 10.1111/tid.13652
   PubMed Web of Science ®Google Scholar
• Abdel-Hafez Y, Siaj H, Janajri M, et al. Tolerability and epidemiology of nephrotoxicity associated with conventional amphotericin B therapy: a retrospective study in tertiary care centers in Palestine. BMC Nephrol. 2022;23(1):132. doi: 10.1186/s12882-022-02770-2
   PubMed Web of Science ®Google Scholar
• Borman AM, Palmer MD, Fraser M, et al. COVID-19-associated invasive aspergillosis: data from the UK national mycology reference laboratory. J Clin Microbiol. 2020;59(1):e02136–20. doi: 10.1128/JCM.02136-20
   PubMed Web of Science ®Google Scholar
• Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149–62. doi: 10.1016/S1473-3099(20)30847-1
   PubMed Web of Science ®Google Scholar
• Marta G-C, Lorena F-E, Laura M-V, et al. COVID-19-associated pulmonary aspergillosis in a tertiary hospital. J Fungi. 2022;8(2):97. doi: 10.3390/jof8020097
   Web of Science ®Google Scholar
• Meijer EFJ, Dofferhoff ASM, Hoiting O, et al. COVID-19–associated pulmonary aspergillosis: a prospective single-center dual case series. Mycoses. 2021;64(4):457–464. doi: 10.1111/myc.13254
   PubMed Web of Science ®Google Scholar
• Patil A, Mohanty HS, Kumar S, et al. Angioinvasive rhinocerebral mucormycosis with complete unilateral thrombosis of internal carotid artery—case report and review of literature. BJR Case Rep. 2016;2(2):20150448. doi: 10.1259/bjrcr.20150448
   PubMedGoogle Scholar
• Ghelfenstein-Ferreira T, Verdurme L, Alanio A. Analytical performance of the commercial MucorGenius® assay as compared to an in-house qPCR assay to detect Mucorales DNA in serum specimens. J Fungi. 2022;8(8):786. doi: 10.3390/jof8080786
   Web of Science ®Google Scholar
• Imbert S, Portejoie L, Pfister E, et al. A multiplex PCR and DNA-sequencing workflow on serum for the diagnosis and species identification for invasive aspergillosis and mucormycosis. J Clin Microbiol. 2023;61(1):1. doi: 10.1128/jcm.01409-22
   Web of Science ®Google Scholar
• Rai P, Singh AK, Anand KB, et al. Time versus tissue: timely identification of Scedosporium rhinosinusitis in a post-COVID-19 case by MALDI-TOF MS leading to successful management. Med J Armed Forces India. 2022;78(3):360–364. doi: 10.1016/j.mjafi.2022.01.014
   PubMedGoogle Scholar
• Ramírez-Hinojosa JP, Medrano-Ahumada S, Arenas R, et al. Fungal invasive co-infection due to Aspergillus fumigatus and Rhizopus arrhizus: a rhino-orbital presentation. J Fungi. 2021;7(12):1096. doi: 10.3390/jof7121096
   Web of Science ®Google Scholar
• Singla S, Singh V, Bansal A, et al. Post COVID-19 acute invasive fungal rhinosinusitis caused by Scedosporium apiospermum: a covert pathogen. Int J Otorhinolaryngol Head Neck Surg. 2021;7(7):1187–1192. doi: 10.18203/issn.2454-5929.ijohns20212459
   Google Scholar
• Jain V, Aggarwal A, Shrimali T, et al. Hit or miss: The Dilemma of Specimen Selection for Microbiological Diagnosis of Rhino-Orbital-Cerebral-COVID-Associated Mucormycosis (ROCM-CAM). Infect Disord. 2023;23(1):e160822207524. doi: 10.2174/1871526522666220816110905
   PubMedGoogle Scholar
• Ghonge NP, Nagpal K, Malla S. ‘Black turbinates’ in COVID-associated sino-nasal mucormycosis. Quarterly J Med. 2022;115(12):851–852. doi: 10.1093/qjmed/hcac195
   Google Scholar
• Safter S, Carpenter JS, Roberts TD, et al. The “Black Turbinate” sign: an early MR imaging finding of nasal mucormycosis. Am J Neuroradiol. 2010;31(4):771–774. doi: 10.3174/ajnr.A1808
   PubMed Web of Science ®Google Scholar
• Taylor AM, Vasan K, Wong EH, et al. Black turbinate sign: MRI findings in acute invasive sinusitis. Otolaryngol Case Rep. 2020;17:100222. DOI:10.1016/j.xocr.2020.100222
   Google Scholar
• Nikolai O, Rohardt C, Tobian F, et al. Anterior nasal versus nasal mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or professional collection matter? Infect Dis (Lond). 2021;53(12):947–952. doi: 10.1080/23744235.2021.1969426
   PubMed Web of Science ®Google Scholar
• Hamid H, Khurshid Z, Adanir N, et al. COVID-19 pandemic and role of human saliva as a testing biofluid in point-of-care technology. Eur J Dent. 2020;14(S 01):S123–S129. doi: 10.1055/s-0040-1713020
   PubMedGoogle Scholar
• Kumar R, Misra AK, Dutta S, et al. A systematic review of mucormycosis cases in COVID-19: is it an unholy trilogy of COVID-19, diabetes mellitus, and corticosteroids? J Family Med Prim Care. 2022;11(6):2573–2580. doi: 10.4103/jfmpc.jfmpc_1934_21
   PubMedGoogle Scholar
• Nehara HR, Puri I, Kumar V, et al. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. Indian J Med Microbiol. 2021;39(3):380–383. doi: 10.1016/j.ijmmb.2021.05.009
   PubMed Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NAR, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13. doi: 10.1126/scitranslmed.3004404
   PubMed Web of Science ®Google Scholar
• WHO Fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Land KJ, Boeras DI, Chen X-S, et al. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. Nat Microbiol. 2019;4(1):46–54. doi: 10.1038/s41564-018-0295-3
   PubMed Web of Science ®Google Scholar